Updated: Sep 13, 2018
***Anakinra, has been approved!***
The specific conditions for which anakinra is under consideration are: - Familial Mediterranean fever (FMF) - Hyperimmunoglobulin D Syndrome, (HIDS) also known as - Mevalonate Kinase Deficiency (MKD) - Tumour necrosis factor receptor–associated periodic syndrome (TRAPS), - Schnitzler syndrome
As a registered stakeholder of the Immunology and Allergy SCG, and, after collaborating with the Autoinflammatory Alliance to provide feedback on the consultation back in February, we asked for patients QoL to be considered during drug monitoring, and not just blood results. We are pleased to see that this has been taken on board in it's new Clinical Commissioning Policy.